Dr Reddy's share price jumped almost 4% during Wednesday’s trading session after Nuvama Institutional Equities, a brokerage firm, raised its rating on the stock from ‘Reduce’ to ‘Buy,’ setting a target price of ₹1,553. The brokerage noted that the expiration of the Revlimid patent in 2026 presents a considerable risk to Dr Reddy's earnings growth, as the medication accounts for …
